Navigation Links
King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology
Date:10/31/2007

48 hours following the onset of moderate to severe pain following bunionectomy surgery. This pivotal Phase 3 clinical trial began enrolling patients in September with a final study report expected in the second half of 2008.

About King Pharmaceuticals

King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and life-cycle management.

About Acura Pharmaceuticals

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of innovative Aversion(R) (abuse deterrent) Technology and related product candidates.

Forward-looking Statements

This release contains forward-looking statements which reflect managements' current views of future events and operations, including, but not limited to, statements pertaining to the expected benefits to the companies' shareholders as a result of the Agreement; statements pertaining to the potential of the Aversion(R) Technology and SABER(TM) formulation technology to reduce some common methods of abuse of opioids; statements pertaining to the expected timetable for the ACUROX(TM) Tablets Phase 3 clinical trial; and statements pertaining to the potential for the companies to successfully develop multiple future products. These forward-looking statements involve certain significant risks and uncertainties, and actual results may differ materially from the forward-looking statements. Some important factors which may cause actual results to differ materially from the forward-looking statements include dependence on the successful development and co
'/>"/>

SOURCE King Pharmaceuticals, Inc.; Acura Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... TALLAHASSEE, Fla. -- A Florida State University C...ang has discovered an important new layer of regul... to a greater understanding of the way cancer begi... sciences at the College of Medicine, said the fin... cancer and could lead to the design of new drugs ...
(Date:11/21/2008)...RISBURG, Pa., Nov. 21 ... Governor Edward G. Rendell today remembered Lieut... teacher, an important partner in public service, ...ania. , , "As the first woman elected lieut...public servant," said Governor Rendell. "Her famil...
(Date:11/21/2008)...SON, Ariz., Nov. 21 The ...today announced that Craig A. Norris, the Company,...the Company,s Board of,Directors. Mr. Norris, ap...,resignation of Steven I. Geringer and returns th...e on any committee of the Board. , Mr. Norr...
(Date:11/21/2008)... researchers remain cautious about future antibiot...FRIDAY, Nov. 21 (HealthDay News) -- People with mo...ease (COPD) may be able to reduce the frequency of...mmon antibiotic, a new report says. , The stud...e American Journal of Respiratory and Critical Ca...
Breaking Medicine News(10 mins):Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 2Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 3Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:Long-Term Erythromycin Cut COPD Complications 2
People who have a low response to alcohol or the so called ability to
...have strong addiction to it."I'd say that there is...es the high I get from gambling," said one addict/...cross Canada recently, thereby, creating more attr...s. According to some experts, this has led to the ...
...drug resistant bacterial infections scientists hav...stop the bacteria’s ability to spread infection//....ign rather killed. This development shows promise ...ht of several antibiotics losing their potency aga...
... department on September 10, sent a warning agains... areas in and around the capital//. From this ye... cases of dengue have been reported, said the depa...he outbreak, the health department is working in c...
Other Medicine News:Health News:Compulsive Gambling – a psychiatric disorde 2Health News:Latest Weapon in Battle against Drug-Resistant Bacteria 2Health News:‘Search and Destroy’ operation against dengue mosquitoes in Philippin 2
(Date:11/21/2008)... Calif., Nov. 21 Amgen,...n Committee for Medicinal,Products for Human Use ...,marketing authorisation for Nplate(TM) (romiplost...nds Nplate for adult chronic immune (idiopathic),...ents who are refractory to,other treatments (e.g....
(Date:11/20/2008)....J., Nov. 20 New Jersey American W...isory for its customers in the following municipal..., , Middlesex County , , , Du... Piscataway , South Plainfield , , ...und Brook , Bridgewater , Green Broo...
(Date:11/20/2008)...lif., Nov. 20 Bionovo, I...present results from the Phase 1B,clinical trial ...ic breast,cancer, BZL101, at the Society for Inte... in Atlanta, Georgia. The Company,s oral presenta...ill be presented as a part of the Best of the,SIO...
(Date:11/20/2008)...rway, November 20 The Scandinavian...as announced results of studies on its,lead antim...Washington, DC,the studies showed that the novel...cidal effect, significantly better towards killing... than marketed gold standard drugs. In,addition t...
Breaking Medicine Technology:Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 2Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 3Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 4Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 5Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 6Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 7Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 8New Jersey American Water Lifts Precautionary Boil Water Advisory For Middlesex, Somerset and Union Counties 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2New Hampshire Seniors Speak Out Against Medicare Advantage Cuts 23522 1New Hampshire Seniors Speak Out Against Medicare Advantage Cuts 23522 2Lilly to Acquire SGX Pharmaceuticals 6431 1Lilly to Acquire SGX Pharmaceuticals 6431 2Lilly to Acquire SGX Pharmaceuticals 6431 3Lilly to Acquire SGX Pharmaceuticals 6431 4Lilly to Acquire SGX Pharmaceuticals 6431 5Awareness of epidemiologys limitations could reduce impact of false positive cancer results 23521 1Awareness of epidemiologys limitations could reduce impact of false positive cancer results 23521 2Also in the July 8 JNCI 23519 1Also in the July 8 JNCI 23519 2Also in the July 8 JNCI 23519 3Also in the July 8 JNCI 23519 4
...IRE)--Jun 18, 2007 - Salix,Pharmaceuticals, Ltd. (...tion and outcome of its Phase III registration tri...00 mg tablet,formulation of balsalazide disodium (...active ingredient in COLAZAL(R),Capsules 750 mg, a... the treatment of mildly to moderately active ulce...
...n achieved at 8 am versus placebo: - 25,/ - 13 mm ...ction dependent on vaccine dose and induced,antian...resented today at the Seventeenth European,Meeting...ich), Switzerland and MILAN, Italy, June 17, 2007 ...y new clinical data,on its hypertension vaccine CY...
Other Medicine Technology:Salix Pharmaceuticals Announces Positive Top Line Results of,Balsalazide Tablets Registration Study 2Salix Pharmaceuticals Announces Positive Top Line Results of,Balsalazide Tablets Registration Study 3Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 2Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 3Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 4Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 5Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 6Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 7Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 8Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 9
...ing tasks such as prescription writing, referral l...c. Your office will be ,able to add more appointme...ff., Based on the exam documentation created by th...ommend the appropriate E&M ,code for the visit - t...
... is an Electronic Medical Office (EMO) for the Oph... of your practice. In addition to retrieving and s...ically integrates the patient office flow includin... about patients, and billing information. ChartLog...
Access your patients' electronic medical records over the Internet with CardioChart. As a Web-enabled software application, physicians and clinicians can pull up a patient's cardiology and vascular m
... is a revolutionary Electronic Medical Office (EMO...stomized for the unique needs of your practice. Th...lectronic record system (EMR, EHR, and EPR), and t...fficiency and performance. In addition to retrievi...
Medicine Products: